Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Genie®, a leading innovator in garage door openers and home security products, proudly announces the release of its newest innovation: a residential linear actuator gate operator designed for ...

Ontario's financial services regulator, FSRA, has imposed an administrative penalty in the amount of $15,000 and a compliance order to cease and desist administering mortgages in Ontario on Razer ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the ...

Eli Lilly and Purdue ... funding cuts to vital research. Lilly CEO Dave Ricks and Purdue University President Mung Chiang on May 9 announced a $250 million collaboration to build up pharmaceutical ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over ...

Co-development of precision RNA therapeutics for inherited hearing loss treatmentSEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company ...